Evaluation of Safety & Efficacy of Nepafenac Eye Drops & Its Comparison with Prednisolone Eye Drops In Ocular Inflammation In Patients Following Uncomplicated Cataract Surgery
DOI:
https://doi.org/10.46858/dvvpf.j.Keywords:
Inflammation, Cataract surgery, Nepafenac, PrednisoloneAbstract
Aims: 1. To evaluate the efficacy of Nepafenac eye drops (0.1%) in ocular inflammation following cataract surgery and monitor its adverse effects, if any. 2. To compare its anti-inflammatory properties with Prednisolone eye drops (1%). Methodology: Study was conducted in a tertiary eye care government hospital. It was Prospective, single-blinded, randomized, single centre clinical study. Group A (100 CCPE, 50 SICS) received nepafenac eye drops & group B (100 CCPE, 50 SICS) received prednisolone eye drops for six weeks. The patients were examined on day 1, 1st, 3rd & 6th week for signs of inflammation. Ocular inflammation was graded using standard classification. Statistical analysis used: Z-test of significance to compare efficacy of the drugs and student t test to compare efficacy in pain management. Results: On follow up, both Group A and group B did not show any statistically significant difference related to the grade of inflammation in anterior chamber (p>0.005). Pain perception was less in the patients in Group A and was statistically significant (p<0.005). Conclusions: Nepafenac eye drop was equally efficacious as prednisolone and no side-effects of nepafenac were noted during the study.
Downloads
References
Robbins, S.L; Angell, M Kumar, “Inflammation and Repair”; in “Basic Pathology”; W.B. Saunders company, Philadelphia 1981;28-60.
Spector, W.G. and Willoughby, D.A.“The demonstration of the role of mediation in Turpentine pleurisy in rats by experimental suppression of the inflammatory cleavages”; J.Path.Bact 1959;77:1-3.
Corboy JM.Corticosteroid therapy for the reduction of post- operative inflammation after cataract surgery.Am J Ophthalmol 1976;82:923.
Burde RM, Waltman SR.Topical corticosteroids after cataract surgery.Ann Ophthalmol 1972;4:290.
Leopold IH.The steroid shield in ophthalmology. Trans Am Acad Ophthalmol Otolaryngol 1967;71:273-289.
Duke–Elder S, Ashton N.Action of cortisone on tissue reactions in inflammation and repair with special reference to the eye. Br J Ophthalmol 1951;35:695-707.
Schanzlin DJ, Goldberg DB, Brown SI.Staphylococcus epidermidis endophthalmitis following intraocular lens implantation. Br J Ophthalmol 1980;64:684.
Armaly MF. Statistical attributes of the steroid hypertensive response in the clinically normal eye.The demonstration of three level response.Invest Ophthalmol 1965;4:187-97.
Becker B, Mills DW. Corticosteroids and intraocular pressure.Arch Ophthalmol 1963;70:500-7.
Martins JC, Wilensky JT Asseff CF et al.Corticosteroid-induced uveitis.Am J Ophthalmol 1974;77:433.
Newsome DA, Wong VG, Cameron TP, Anderson RR ."Steroid-induced" mydriasis and ptosis.Invest Ophthalmol 1971;10:424.
Brennan KM, Brown RM, Roberts CW. A comparison of topical nonsteroidal anti-infl ammatory drugs to steroids for control of post cataract inflammation. J Am Soc Ophthalmic Reg Nurses.1993;XVIII:8–11.
Simone JN, Pendelton RA, Jenkins JE.Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery. J Cataract Refract Surg.1999;25:699–704.
Reddy MS, Suneetha N, Thomas RK, Battu RR. Topical diclofenac sodium for treatment of postoperative infl ammation in cataract surgery. Indian J Ophthalmol.2000;48:223–6.
Lane SS, Modi SS, Lehmann RP, Holland EJ. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg. 2007;33:53-8.
Flower RJ, Blackwell GJ. Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor.Nature.1979;278-456.
Lee RE. The influence of psychotropic drugs on prostaglandin biosynthesis. Prostaglandins.1974;5:63.
O’Brien TP.Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care.Curr Med Res Opin 2005; 21:1131-37.
Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM. Nepafenac, a unique non-steroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation:II.In vitro bioactivation and permeation of external ocular barriers.Inflammation.2000;24:371-84.
Stephan S Lane.Nepafenac:A unique non-steroidal prodrug.Int Ophthalmol Clin 2006;46:13-20.Stewart WC. April 2005. Pre-operative and postoperative clinical evaluation of nepafenac 0.1% ophthalmic suspension for postcataract infl ammation. Presented at the 2005 ASCRS meeting. Washington, DC.
Hossain MM, Mohiuddin AA, Hossain MA, Aziz MA. Diclofenac sodium and prednisolone acetate ophthalmic solution in controlling inflammation after cataract surgery. Mymensingh Med J. 2010;19:343-7.
Demco TA, Sutton H, Demco CJ, Raj PS. Topical diclofenac sodium compared with prednisolone acetate after phacoemulsification-lens implant surgery. Eur J Ophthalmol. 1997;7:236-40.
el-Harazi SM, Ruiz RS, Feldman RM, Villanueva G, Chuang AZ. A randomized double-masked trial comparing ketorolac tromethamine 0.5%, diclofenac sodium 0.1%, and prednisolone acetate 1% in reducing post-phacoemulsification flare and cells. Ophthalmic Surg Lasers. 1998;29:539-44.
Nagpal M, Lambat S, Mehrotra N, Paranjpe G, Yadav H, Bhardwaj S. Topical nepafenac 0.1% alone versus prednisolone acetate 1% as postoperative anti-inflammatory agents in small gauge vitrectomy. Indian J Ophthalmol.2014;62:606-9.
Di Pascuale MA, Whitson JT, Mootha VV. Corneal melting after use of nepafenac in a patient with chronic cystoid macular edema after cataract surgery. Eye Contact Lens.2008;34:129-30.
Wolf EJ, Kleiman LZ, Schrier A. Nepafenac-associated corneal melt. J Cataract Refract Surg.2007;33:1974-5.
